News Headlines Article

Lawmakers look to repeal Medicare provision aiding Amgen drug
Los Angeles Times

A bipartisan group of U.S. lawmakers is seeking to repeal a Medicare-pricing provision in the recent “fiscal cliff” deal that benefits biotech giant Amgen Inc.

U.S. Rep. Peter Welch (D-Vt.) filed legislation this week to eliminate the exemption for a class of drugs, including Amgen’s Sensipar, that are used by kidney dialysis patients.

The fiscal-cliff legislation approved earlier this month excluded these oral medications from Medicare price controls for an additional two years.